MedTrace Logo

Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies

NCT03739931 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 134

Last updated 2025-08-15

No results posted yet for this study

Summary

The clinical study will assess the safety and tolerability of escalating intratumoral doses of mRNA-2752 in participants with relapsed/refractory solid tumor malignancies or lymphoma.

Conditions

  • Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma
  • Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma

Interventions

BIOLOGICAL

mRNA-2752

Solution for intratumoral injection

BIOLOGICAL

Durvalumab

Solution for infusion after dilution

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • ModernaTX, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-27
Primary Completion
2025-08-01
Completion
2025-08-01
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Israel

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03739931 on ClinicalTrials.gov